Follow @TheHPRA
Contact us
As Gaeilge
My HPRA:
Login
Register
About Us
Medicines
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Medicines
Safety Notices
My HPRA:
Login
Register
About Us
Medicines
COVID-19 vaccines and treatments
Our Role
Medicines Information
Safety Information
Safety Notices
Quality Information
Regulatory Information
News & Events
Special Topics
Emergency Medicines
Emergency Contact Details
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
EMEA recommends changes in the storage conditions for Neupro (rotigotine)
Notice type:
Advisory
Date:
04/06/2008
Product name or type:
Neupro Transdermal Patches (rotigotine)
Active Substance:
Rotigotine
Target Audience:
Healthcare Professionals
Pharmacists
Wholesalers of Medicinal Products
General Public
Problem Or Issue:
The European Medicines Agency (EMEA) has recommended the immediate implementation of changes to the product information for Neupro (rotigotine), from Schwarz Pharma Ltd, stating that it must be stored in a refrigerator (at a temperature of between 2ºC and 8ºC). The new storage conditions are intended to reduce the possible occurrence of crystallisation of the active substance which has been reported in patches of Neupro.
Background Information Or Related Documents:
EMEA recommends changes in the storage conditions for Neupro (rotigotine) Document
Further Information:
For further information,
click
here to read the Press Release
and
Q&A document
.
« Back
Date Printed: 22/09/2023